Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone thearpy in endometrial carcinomas

Journal of Pathology

Volumn 182, Issue 4, 1997, Pages 429-436

  Saegusa, Makoto ^a   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

bcl 2; endometrial carcinoma; ER; hormone therapy; Ki 67; PR

Indexed keywords

ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ARTICLE; CANCER HORMONE THERAPY; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SQUAMOUS CELL METAPLASIA;

CARCINOMA, SQUAMOUS CELL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 0030749616     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199708)182:4<429::AID-PATH872>3.0.CO;2-Z     Document Type: Article

References (20)

1. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359: 554-556.
2. Oltvai ZN, Milliman CL, Korsmeyer SJ. bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
3. Saegusa M, Takano Y, Hashimura M, Shoji Y, Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer 1995; 76: 2297-2303.
4. Saegusa M, Takano Y, Okayasu I. bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995; 121: 357-363.
5. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: regulation of cell death. Blood 1992; 80: 879-886.
6. Saegusa M, Kamata Y, Isono M, Okayasu I. bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 1996; 180: 275-282.
7. Novack DV, Korsmeyer SJ. bcl-2 protein expression during murine development. Am J Pathol 1994; 145: 61-73.
8. Lu Q-L, Poulsom R, Wong L, Hanby AM. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993; 169: 431-437.
9. Elton NW. Adenocarcinoma of fundus. Am J Clin Pathol 1942; 12: 32-47.
10. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961: 264: 216-222.
11. Creasman WT. Announcement, FIGO stages: 1988 revision. Gynecol Oncol 1989; 35: 125-127.
12. Poulsen CE, Taylor CW, Sobin LH. International Histological Classification of Tumors: Histologiesl Typing of Female Genital Tract Tumors. No. 13. Geneva: World Health Organization, 1975.
13. Lu Q-L, Abel P, Foster CS, Lalani E-N. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-110.
14. Benito A, Grillot D, Nunez G, Fernandez-Luna JL. Regulation and function of bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am J Pathol 1995; 146: 481-490.
15. Krajewski S, Chatten J, Hanada M, Reed JC. Immunohistochemical analysis of the bcl-2 oncoprotein in human neuroblastomas: comparison with tumor cell differentiation and N-myc protein. Lab Invest 1995; 71: 42-54.
16. Chan WK, Mole MM, Levison DA, et al. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 1995; 177: 241-246.
17. Otsuki Y, Misaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 1994; 344: 28-29.
18. Gompel A, Sabourin JC, Martin A, et al. bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994; 144: 1195-1202.
19. Teixeira C, Reed JC, Pratt MAC. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
20. Cohen CJ, Rahaman J. Endometrial cancer: management of high risk and recurrence including the tamoxifen controversy. Cancer 1995; 76: 2044-2052.